Judith Ng-Cashin
Keine laufenden Positionen mehr
Profil
Judith Ng-Cashin served as the Chief Medical Officer at AOBiome Therapeutics, Inc. She also served as the Chief Medical Officer and Executive Vice President at Eagle Pharmaceuticals, Inc. Prior to her professional roles, she earned an undergraduate degree from Duke University and a doctorate from Rush Medical College.
Ehemalige bekannte Positionen von Judith Ng-Cashin
Unternehmen | Position | Ende |
---|---|---|
EAGLE PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 27.12.2021 |
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Judith Ng-Cashin
Duke University | Undergraduate Degree |
Rush Medical College | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
EAGLE PHARMACEUTICALS, INC. | Health Technology |
Private Unternehmen | 1 |
---|---|
AOBiome Therapeutics, Inc.
AOBiome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AOBiome Therapeutics, Inc. develops microbiome-targeted therapies for local, nasal and systemic inflammatory conditions. Its portfolio includes three clinical-stage programs, a Phase 2b study to treat patients with acne vulgaris, a Phase 2 trial to reduce elevated blood pressure, and a Phase 1b/2a clinical trial in allergic rhinitis, as well as earlier-stage preclinical programs targeting diverse inflammatory indications. The company was founded by Jamie Heywood, David Whitlock and Lenny Barshack in 2013 and is headquartered in Cambridge, MA. | Health Technology |